nach oben

Strahlentherapie und Onkologie

Erschienen in:

01.05.2013 | Übersichten

Oligometastases: the new paradigm and options for radiotherapy

A critical review

verfasst von: H. Badakhshi, MD, A. Grün, MD, C. Stromberger, MD, V. Budach, MD PhD, D. Boehmer, MD PhD

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 5/2013

Einloggen, um Zugang zu erhalten

Abstract

Traditional oncology distinguishes between two separate and incommensurable states in the evolution of solid malignancies: the localized disease, which is curable; and the disseminated status, which is per se palliative. Recently, a huge body of evidence suggests a fundamental change in the understanding of cancer, indicating an intermediate state in the trajectory of solid malignancies: the oligometastatic state. The following review will critically analyse existing hypotheses and facts from the basic sciences and try to contextualize it in regard to the clinical evidence available to date. Consecutively, it will try to draw possible clinical consequences for application of radiotherapy in this specific clinical scenario.

Chaffer CL, Weinberg RA (2011) A perspective on cancer cell metastasis. Science 331(6024):1559–1564PubMedCrossRef

Hellman S (1994) Karnofsky memorial lecture. Natural history of small breast cancers. J Clin Oncol 12(10):2229–2234PubMed

Fisher B (1980) Laboratory and clinical research in breast cancer—a personal adventure: the David A Karnovsky Memorial Lecture. Cancer Res 40:3863–3874PubMed

Hellman S, Weichselbaum RR (1995) Oligometastases. J Clin Oncol 13:8–10PubMed

Gupta GP, Massagué J (2006) Cancer metastasis: building a Framework. Cell 127:679–695PubMedCrossRef

Fielder IJ (2003) The pathogeneis of cancer metatsis: the “seed and soil” hypothesis revisited. Nat Rev Cancer 3:1–6

Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100(1):57–70PubMedCrossRef

Harris AL (2002) Hypoxia—a key regulatory factor in tumour growth. Nat Rev Cancer 2(1):38–47PubMedCrossRef

Semenza GL (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3(10):721–732PubMedCrossRef

10.

Wong CC, Gilkes DM, Zhang H et al (2011) Hypoxia-inducible factor 1 is a master regulator of breast cancer metastatic niche formation. Proc Natl Acad Sci U S A 108(39):16369–16374PubMedCrossRef

11.

Bonnet D, Dick JE (1997) Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nature Med 3(7):730–737PubMedCrossRef

12.

Al-Hajj M, Wicha MS, Benito-Hernandez A et al (2003) Prospective identification of tumorigenic breast cancer cells. Proceedings of the National Academy of Sciences of the United States of America. 100(7):3983–3988

13.

Fang D, Nguyen TK, Leishear K et al (2005) A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 65(20):9328–9337PubMedCrossRef

14.

Lorico A, Rappa G (2011) Phenotypic heterogeneity of breast cancer stem cells. J Oncol 2011:135039PubMedCrossRef

15.

Dewi DL, Ishii H, Kano Y et al (2011) Cancer stem cell theory in gastrointestinal malignancies: recent progress and upcoming challenges. J Gastroenterol 46(10):1145–1157PubMedCrossRef

16.

Cheng L, Alexander R, Zhang S et al (2011) The clinical and therapeutic implications of cancer stem cell biology. Expert Rev Anticancer Ther 11(7):1131–1143PubMedCrossRef

17.

Tang DG (2012) Understanding cancer stem cell heterogeneity and plasticity. Cell Res 22(3):457–472PubMedCrossRef

18.

Quail DF, Taylor MJ, Postovit LM (2012) Microenvironmental regulation of cancer stem cell phenotypes. Curr Stem Cell Res Ther 7(3):197–216PubMedCrossRef

19.

Clarke MF, Dick JE, Dirks PB et al (2006) Cancer stem cells—perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 66:9339–9344PubMedCrossRef

20.

Reya T, Morrison SJ, Clarke MF, Weissman IL (2001) Stem cells, cancer, and cancer stem cells. Nature 414:105–111PubMedCrossRef

21.

Quintana E, Shackleton M, Sabel MS et al (2008) Efficient tumour formation by single human melanoma cells. Nature 456(7222):593–598PubMedCrossRef

22.

Thiery JP, Sleeman JP (2006) Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 7:131–142PubMedCrossRef

23.

Mani SA, Guo W, Liao MJ et al (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133(4):704–715PubMedCrossRef

24.

Peinado H, Olmeda D, Cano A (2007) Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer 7:415–428PubMedCrossRef

25.

Bekes EM, Schweighofer B, Kupriyanova TA et al (2011) Tumor-recruited neutrophils and neutrophil TIMP-free MMP-9 regulate coordinately the levels of tumor angiogenesis and efficiency of malignant cell intravasation. Am J Pathol 179(3):1455–1470PubMedCrossRef

26.

Weichselbaum RR, Hellman S (2011) Oligometastases revisited. Nat Rev Clin Oncol 8:378–382PubMed

27.

D’Agostino GR, Autorino R, Pompucci A et al (2011) Whole-brain radiotherapy combined with surgery or stereotactic radiotherapy in patients with brain oligometastases: long-term analysis. Strahlenther Onkol 187(7):421–425CrossRef

28.

Scorsetti M, Mancosu P, Navarria P et al (2011) Stereotactic body radiation therapy (SBRT) for adrenal metastases: a feasibility study of advanced techniques with modulated photons and protons. Strahlenther Onkol 187(4):238–244PubMedCrossRef

29.

Holy R, Piroth M, Pinkawa M, Eble MJ (2011) Stereotactic body radiation therapy (SBRT) for treatment of adrenal gland metastases from non-small cell lung cancer. Strahlenther Onkol 187(4):245–251PubMedCrossRef

30.

Rusthoven KE, Kavanagh BD, Burri SH et al (2009) Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. J Clin Oncol 27:1579–1584PubMedCrossRef

31.

Ricke J, Mohnike K, Pech M et al (2010) Local response and impact on survival after local ablation of liver metastases from colorectal carcinoma by computed tomography-guided high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys 78:479–485PubMedCrossRef

32.

Milano MT, Zhang H, Metcalfe SK et al (2009) Oligometastatic breast cancer treated with curative-intent stereotactic body radiation therapy. Breast Cancer Res Treat 115:601PubMedCrossRef

33.

Okunieff P, Petersen AL, Philip A et al (2006) Stereotactic body radiation therapy (SBRT) for lung metastases. Acta Oncol 45(7):808–817PubMedCrossRef

34.

Yoon SM, Choi EK, Lee SW et al (2006) Clinical results of stereotactic body frame based fractionated radiation therapy for primary or metastatic thoracic tumours. Acta Oncol 45:1108–1114PubMedCrossRef

35.

Ricardi U, Filippi AR, Guarneri A et al (2012) Stereotactic body radiation therapy for lung metastases. Lung Cancer 75(1):77–81PubMedCrossRef

36.

Pawlik TM, Scoggins CR, Zorzi D et al (2005) Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg 241(5):715–724PubMedCrossRef

37.

Mendez Romero A, Wunderink W, Hussain SM et al (2006) Stereotactic body radiation therapy for primary and metastatic liver tumors: a single institution phase I–II study. Acta Oncol 45:831–837CrossRef

38.

Rusthoven KE, Kavanagh BD, Cardenes H et al (2009) Multiinstitutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol 27(10):1572–1578PubMedCrossRef

39.

Fumagalli I, Bibault JE, Dewas S et al (2012) A single-institution study of stereotactic body radiotherapy for patients with unresectable visceral pulmonary or hepatic oligometastases. Radiat Oncol 7(1):164PubMedCrossRef

40.

Ricke J, Wust P (2011) Computed tomography-guided brachytherapy for liver cancer. Semin Radiat Oncol 21(4):287–293PubMedCrossRef

41.

Wieners G, Mohnike K, Peters N et al (2011) Treatment of hepatic metastases of breast cancer with CT-guided interstitial brachytherapy—a phase II-study. Radiother Oncol 100(2):314–319PubMedCrossRef

42.

Rades D, Kueter JD, Gliemroth J et al (2012) Resection plus whole-brain irradiation versus resection plus whole-brain irradiation plus boost for the treatment of single brain metastasis. Strahlenther Onkol 188(2):143–147PubMedCrossRef

43.

Andrews DW, Scott CB, Sperduto PW et al (2004) Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 363:1665–1672PubMedCrossRef

44.

Aoyama H, Shirato H, Tago M et al (2006) Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA 295:2483–2491PubMedCrossRef

45.

Kocher M, Soffietti R, Abacioglu U et al (2011) Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol 29:134–141PubMedCrossRef

46.

Rades D, Hakim SG, Bajrovic A et al (2012) Impact of zoledronic acid on control of metastatic spinal cord compression. Strahlenther Onkol 188(10):910–916PubMedCrossRef

47.

Nguyen QN, Shiu AS, Rhines LD et al (2010) Management of spinal metastases from renal cell carcinoma using stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 76:1185–1192PubMedCrossRef

48.

Gerszten PC, Burton SA, Ozhasoglu C et al (2007) Radiosurgery for spinal metastases: clinical experience in 500 cases from a single institution. Spine 32:193–199PubMedCrossRef

49.

Brown WT, Wu X, Fowler JF et al (2008) Lung metastases treated by CyberKnife image-guided robotic stereotactic radiosurgery at 41 months. South Med J 101:376–382PubMedCrossRef

50.

Norihisa Y, Nagata Y, Takayama K et al (2008) Stereotactic body radiotherapy for oligometastatic lung tumours. Int J Radiat Oncol Biol Phys 72:398–403PubMedCrossRef

51.

Lee MT, Kim JJ, Dinniwell R et al (2009) Phase I study of individualized stereotactic body radiotherapy of livermetastases. J Clin Oncol 27(10):1585–1591PubMedCrossRef

52.

Ambrosino G, Polistina F, Costantin G et al (2009) Image-guided robotic stereotactic radiosurgery for unresectable liver metastases: preliminary results. Anticancer Res 29:3381–3384PubMed

53.

Herfarth KK, Debus J, Lohr F et al (2001) Stereotactic single-dose radiation therapy of liver tumors: results of a phase I/II trial. J Clin Oncol 19:164–170PubMed

54.

Rule W, Timmerman R, Tong L et al (2011) Phase I dose-escalation study of stereotactic body radiotherapy in patients with hepatic metastases Ann Surg Oncol 18(4):1081–1087

55.

Manon R, O’Neill A, Knisely J et al (2005) Eastern Cooperative Oncology Group. Phase II trial of radiosurgery for one to three newly diagnosed brain metastases from renal cell carcinoma, melanoma, and sarcoma: an Eastern Cooperative Oncology Group study (E 6397). J Clin Oncol 23:8870–8876PubMedCrossRef

56.

Sanghavi SN, Miranpuri SS, Chappell R et al (2001) Radiosurgery for patients with brain metastases: a multi-institutional analysis, stratified by the RTOG recursive partitioning analysis method. Int J Radiat Oncol Biol Phys 51:426–434PubMedCrossRef

57.

Tsai JT, Lin JW, Chiu WT et al (2009) Assessment of image- guided CyberKnife radiosurgery for metastatic spine tumors. J Neuroncol 94:119–127CrossRef

58.

Yamada Y, Bilsky MH, Lovelock DM et al (2008) Highdose single-fraction image-guided intensity-modulated radiotherapy for metastatic spinal lesions. Int J Radiat Oncol Biol Phys 71:484–490PubMedCrossRef

59.

Gibbs IC, Kamnerdsupaphon P, Ryu MR et al (2007) Image-guided robotic radiosurgery for spinal metastases. Radiother Oncol 82:185–190PubMedCrossRef

60.

Ryu S, Fang Yin F, Rock J et al (2003) Image-guided and intensity-modulated radiosurgery for patients with spinal metastasis. Cancer 97:2013–2018PubMedCrossRef

Titel: Oligometastases: the new paradigm and options for radiotherapy
A critical review
verfasst von: H. Badakhshi, MD
A. Grün, MD
C. Stromberger, MD
V. Budach, MD PhD
D. Boehmer, MD PhD
Publikationsdatum: 01.05.2013
Verlag: Springer-Verlag
Erschienen in: Strahlentherapie und Onkologie / Ausgabe 5/2013
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-013-0326-1

Springer Medizin

Oligometastases: the new paradigm and options for radiotherapy

A critical review

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2013

Radiotherapy for carcinoma of the vagina

Validation of a survival score for patients treated with whole-brain radiotherapy for brain metastases

Adjuvant IMRT/XELOX radiochemotherapy improves long-term overall- and disease-free survival in advanced gastric cancer

Physical and psychosocial support requirements of 1,500 patients starting radiotherapy

Mitteilungen der Fachgesellschaften

Quasi-VMAT in high-grade glioma radiation therapy

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie